Our Vice President of Global Biotherapeutic Technologies Will Somers, not only researches potential therapies for hemophilia, he also suffers from the disease.Our team is working to advance novel science, with the goal of developing safe and effective therapies for patients affected by hemophilia and other rare disorders. Learn more about the work of Will’s team and our collaborative approach to hemophilia research